This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Faruqi & Faruqi, LLP Is Investigating Genoptix, Inc. On Behalf Of Its Shareholders - GXDX

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors and Officers of Genoptix, Inc. (“Genoptix” or the “Company”) (NASDAQ: GXDX). The investigation focuses on possible violations of the federal securities laws and breaches of fiduciary duties by Genoptix and certain of its Officers and Directors.

The investigation focuses on allegations that certain statements issued by the Company regarding Genoptix’s business, operations and prospects misrepresented the Company’s financial performance. Specifically, the investigation pertains to the Company's approach to hematology and oncology testing and diagnostics, and the projections that Genoptix would be able to double or triple the size of its market share in a short period of time, while failing to disclose that the Company’s business model was not working and, on the contrary, was causing Genoptix to lose its market share. As a result, Genoptix's stock traded at artificially inflated prices during July 31, 2009 and June 15, 2010, inclusive (the “Class Period”), reaching a high of $38.79 per share on April 30, 2010.

On May 6, 2010, Genoptix issued a press release announcing first quarter 2010 financial results far below consensus. On this news, the Company’s stock fell $8.37 per share to close at $27.89 per share on May 7, 2010, a decline of approximately 23%. Further, on June 16, 2010, Genoptix issued another press release providing a first look at its second quarter 2010 performance and updating its guidance for the full-year 2010. The Company reduced its revenue guidance to $210 million, down from previous guidance of $235 to $240 million, and its earnings per share guidance to $1.20 per share, down from previous guidance of $1.80 to $1.85 per share. On this news, the Company’s stock fell another $5.69 per share to close at $17.19 per share on June 16, 2010, a decline of approximately 25%.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs